Although anti‐HER2 therapy has not been regularly provided for patients with HER2‐low BC until now in China, we still observed a potentially better prognosis for HER2‐low BC than HER2‐zero BC, especially in HR‐negative BC, which was also observed in previous studies.9, 42, 46. Here, ERBB2 is linked to breast cancer.